Ginkgo bioworks receives grant to develop innovative live cell delivery platform of antibody therapeutics for treating hiv and malaria

Ginkgo, under a grant from the bill & melinda gates foundation, will work to develop a live cell therapeutic that can produce antibodies to fight human immunodeficiency virus (hiv) and/or malaria directly in the body ginkgo will apply its cell engineering expertise towards creating a fundamentally new cell-based therapeutic delivery modality which could change the future of biologics delivery in medicine boston , dec. 13, 2023 /prnewswire/ -- – ginkgo bioworks (nyse: dna), which is building the leading platform for cell programming and biosecurity, has received a grant from the bill & melinda gates foundation to develop a novel cell-based technology for improving protein therapeutics delivery for patients in low- and middle-income countries (lmics). protein therapeutics have transformed the standard of care for many diseases — the best known example being insulin for diabetes — and have helped to extend lives across the world, thanks to revolutionizing treatments of diseases such as anemia, cancers, and certain genetic disorders.
DNA Ratings Summary
DNA Quant Ranking